Sema4, Stamford, Conn, has launched Sema4 Signal, a new family of products and services providing data-driven precision oncology solutions with advanced analytics, digital tools, and exome-based somatic and hereditary cancer genomic tests. With its comprehensive suite of offerings, Sema4 Signal enables a holistic approach to support oncologists delivering precision medicine throughout a patient’s journey, from assessing the risk of cancer to analyzing cancer for treatment options and monitoring in remission. “Sema4 Signal, our family of data-driven precision oncology care solutions, was designed to meet the needs of health systems, providers, patients, and payors,” says Eric Schadt, PhD, founder and chief executive officer of Sema4. “We have applied our strong expertise in data science, including artificial intelligence and digital tools, combined with our cutting-edge exome-based genomic testing and commitment to service, to deliver solutions to improve the risk assessment, diagnosis, and treatment of cancer.” Sema4 is partnering with providers and health systems nationwide to support oncology clinical care by structuring and analyzing large data sets of electronic medical records and genomic information, using machine learning and natural language processing tools to draw insights at the individual and cohort level, and helping match patients to the most appropriate clinical trials. The information gleaned through these advanced analytics also enables healthcare administrators to advance research, trial, and quality-of-care programs benefiting their entire patient community. This product launch includes “Sema4 Signal Hereditary Cancer,” a portfolio of hereditary cancer panels composed of a comprehensive 112 gene panel, as well as 16 subpanels delivered with a customizable experience including video-based education, workflow tools, and genetic counseling. Sema4 Signal Hereditary Cancer panels are run on Sema4’s Traversa, an exome-based genomic platform covering thousands of genes identified by medical experts as clinically relevant and actionable. For more information, visit Sema4.